Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review

References

• Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Cancer stat facts: female breast cancer subtypes. https://seer.cancer.gov/statfacts/html/breast-subtypes.html
   Google Scholar
• National Cancer Institute. Institute. Cancer stat facts: female breast cancer. https://seer.cancer.gov/statfacts/html/breast.html
   Google Scholar
• Ballinger TJ, Meier JB, Jansen VM. Current landscape of targeted therapies for hormone-receptor positive, HER2 negative metastatic breast cancer. Front. Oncol. 8, 308 (2018).
   PubMed Web of Science ®Google Scholar
• Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 18(1), 17 (2016).
   PubMed Web of Science ®Google Scholar
• Gennari A, Andre F, Barrios CH et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann. Oncol. 32(12), 1475–1495 (2021).
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 16(1), 25–35 (2015).
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS et al. palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375(20), 1925–1936 (2016).
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 17(4), 425–439 (2016).
   PubMed Web of Science ®Google Scholar
• U.S. FDA. palbociclib (IBRANCE). https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib-ibrance
   Google Scholar
• Rugo HS, Finn RS, Diéras V et al. palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res. Treat. 174(3), 719–729 (2019).
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Rugo HS, Im SA et al. Overall Survival with palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. Clin. Cancer Res. 28(16), 3433–3442 (2022).
   PubMed Web of Science ®Google Scholar
• Finn RS, Boer K, Bondarenko I et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Res. Treat. 183(2), 419–428 (2020).
   PubMed Web of Science ®Google Scholar
• Finn RS, Rugo HS, Dieras VC et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ER+/HER2- ABC): Analyses from PALOMA-2. J. Clin. Oncol. 40(Suppl. 17), LBA1003–LBA1003 (2022).
   Web of Science ®Google Scholar
• Turner NC, Slamon DJ, Ro J et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N. Engl. J. Med. 379(20), 1926–1936 (2018).
   PubMed Web of Science ®Google Scholar
• Chen D. Real-world studies: bridging the gap between trial-assessed efficacy and routine care. J. Biomed. Res. 36(3), 147–154 (2022).
   PubMed Web of Science ®Google Scholar
• Chodankar D. Introduction to real-world evidence studies. Perspect. Clin. Res. 12(3), 171–174 (2021).
   PubMedGoogle Scholar
• Gyawali B, Parsad S, Feinberg BA, Nabhan C. Real-world evidence and randomized studies in the precision oncology era: the right balance. JCO Precis Oncol. 1, 1–5 (2017).
   PubMed Web of Science ®Google Scholar
• Harbeck N, Bartlett M, Spurden D et al. CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies. Future Oncol. 17(16), 2107–2122 (2021).
   PubMed Web of Science ®Google Scholar
• Rugo HS, Brufsky A, Liu X et al. Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer. NPJ Breast Cancer 8(1), 114 (2022).
   PubMed Web of Science ®Google Scholar
• Demichele A, Cristofanilli M, Brufsky A et al. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res. 23(1), 37 (2021).
   PubMed Web of Science ®Google Scholar
• Brufsky A, Liu X, Li B, Mcroy L, Layman RM. Real-world effectiveness of palbociclib plus letrozole vs letrozole alone for metastatic breast cancer with lung or liver metastases: flatiron database analysis. Front. Oncol. 12, 865292 (2022).
   PubMed Web of Science ®Google Scholar
• Ha MJ, Singareeka Raghavendra A, Kettner NM et al. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: a large institutional study. Int. J. Cancer 150(12), 2025–2037 (2022).
   PubMed Web of Science ®Google Scholar
• Porte B, Carton M, Lerebours F et al. Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer. Breast 54, 303–310 (2020).
   PubMed Web of Science ®Google Scholar
• Law JW, Mitra D, Kaplan HG et al. Real-world treatment patterns and clinical effectiveness of palbociclib plus an aromatase inhibitor as first-line therapy in advanced/metastatic breast cancer: analysis from the US syapse Learning health network. Curr. Oncol. 29(2), 1047–1061 (2022).
   PubMed Web of Science ®Google Scholar
• Ali MS, Prieto-Alhambra D, Lopes LC et al. Propensity Score methods in health technology assessment: principles, extended applications, and recent advances. Front. Pharmacol. 10, 973 (2019).
   PubMed Web of Science ®Google Scholar
• Neven P, Fasching PA, Chia S et al. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Res. 25(1), 103 (2023).
   PubMed Web of Science ®Google Scholar
• Goetz MP. MONARCH 3: interim overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor in patients with HR+, HER2- advanced breast cancer. Presented at: ESMO Congress. Paris, France (9-13 september 2022).
   Google Scholar
• Grinshpun A, Tolaney SM, Burstein HJ, Jeselsohn R, Mayer EL. The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer. NPJ Breast Cancer 9(1), 15 (2023).
   PubMed Web of Science ®Google Scholar
• Medicinrådet. Behandlingsvejledning vedrørende CDK4/6-hæmmere til ER+/HER2- lokalt fremskreden eller metastatisk brystkræft (2023). https://medicinraadet.dk/anbefalinger-og-vejledninger/behandlingsvejledninger-og-laegemiddelrekommandationer/brystkraeft
   Google Scholar
• Onesti CE, Jerusalem G. CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Rev. Anticancer Ther. 21(3), 283–298 (2021).
   PubMed Web of Science ®Google Scholar
• Cejuela M, Gil-Torralvo A, Castilla M et al. abemaciclib, palbociclib, and ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer. Int. J. Mol. Sci. 24(10), (2023).
   Web of Science ®Google Scholar